Regulatory reference · Tirzepatide

Tirzepatide (Mounjaro): UK regulatory profile

Tirzepatide is the active substance in the medicinal product marketed as Mounjaro by Eli Lilly. It is a Prescription Only Medicine (POM) in the United Kingdom. This page is editorial regulatory commentary covering the UK MHRA marketing authorisation, mechanism of action, published clinical trial data, and the dispensing pathways available through UK-regulated providers. PeptideClear does not prescribe, dispense, or sell prescription medication.

Mechanism (per MHRA-approved SmPC)

Tirzepatide is a 39-amino-acid synthetic peptide acting as an agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Both incretin hormones are released by the gut following nutrient intake.

According to the Eli Lilly Summary of Product Characteristics, GLP-1 receptor activation slows gastric emptying, modulates appetite signalling, and improves glucose-dependent insulin secretion. GIP receptor activation contributes additional insulinotropic and metabolic effects. The molecule has a plasma half-life of approximately five days, which supports once-weekly subcutaneous administration as set out in the approved product information.

UK MHRA marketing authorisation

· Marketing authorisation holder: Eli Lilly Nederland B.V.
· UK MHRA marketing authorisation for type 2 diabetes: 2022.
· UK MHRA marketing authorisation for chronic weight management: 2024.
· Obstructive sleep apnoea indication: FDA approval December 2024; UK MHRA equivalent indication recognised in early 2026.
· Black Triangle status: under additional MHRA monitoring for real-world safety reporting.
· Authoritative product information: the MHRA-approved Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL) are published on emc.medicines.org.uk.

Dosing, titration, contraindications, warnings, and adverse-event guidance are governed by the SmPC and PIL. PeptideClear does not republish dosing schedules. Please consult the PIL provided with the dispensed medicine and the SmPC linked above.

Published clinical trial data

SURMOUNT-1 (2022): a 72-week randomised controlled trial in 2,539 adults with obesity or overweight with at least one weight-related comorbidity, without type 2 diabetes. Published in the New England Journal of Medicine. Provided the pivotal evidence cited in the MHRA weight-management authorisation.
SURMOUNT-2 (2023): published trial in adults with type 2 diabetes plus obesity. Outcomes in this population are lower than in the non-diabetic SURMOUNT-1 cohort, a pattern consistent across the GLP-1 receptor agonist class.
SURMOUNT-3 and SURMOUNT-4 (2024): trials examining intensive lifestyle intervention plus tirzepatide and weight maintenance after initial response. Provide the published evidence base for continued treatment versus discontinuation.
SURMOUNT-OSA (2024): trial in adults with moderate-to-severe obstructive sleep apnoea and obesity. Supports the regulatory recognition of an OSA indication.
SURPASS series: the published trial programme underpinning the type 2 diabetes marketing authorisation.

Trial summaries are provided for editorial reference. Clinical interpretation for any individual remains the responsibility of a UK-registered prescriber.

UK regulatory and NHS framework

· Prescription Only Medicine under the Human Medicines Regulations 2012. May not be advertised to the public; supply requires a prescription issued by a UK-registered prescriber.
· NICE Technology Appraisal TA1026 governs NHS use for chronic weight management, with a phased cohort rollout.
· Cohort 1 live since June 2025. Cohort 2 commencement: 23 June 2026. Cohort 3 expected April 2027.
· Eligibility, BMI thresholds, and comorbidity criteria are set by NICE and individual Integrated Care Board commissioning policies.

Regulated UK dispensing routes

If a UK-registered prescriber determines that tirzepatide is clinically appropriate, the medicine is dispensed through UK MHRA-licensed pharmacies and CQC-registered clinics under the standard POM framework. The decision on whether tirzepatide is suitable, and on any titration and monitoring schedule, rests with that prescriber.

· NHS pathway: dispensing follows NICE TA1026 eligibility and the NHS prescription charge structure. See NHS GLP-1 access.
· CQC-registered private clinics: consultation, prescribing review, and ongoing clinical support under a registered service. Directory: UK clinics.
· UK MHRA-licensed pharmacies: prescription supply with pharmacist oversight under General Pharmaceutical Council registration. Directory: UK pharmacies.

PeptideClear lists regulated dispensing routes for reference. We do not endorse any specific provider for any specific person. Your prescriber decides.

UK pricing context (2026)

Eli Lilly revised UK list pricing for tirzepatide in September 2025. Editorial commentary on UK private pricing trends, NHS commissioning, and the pricing environment is provided at UK GLP-1 cost and supply. Specific dispensed prices are set by the prescriber or pharmacy at the point of supply and may change.

Related editorial reference

PeptideClear is editorial. We do not prescribe, dispense, or sell prescription medication. The MHRA-approved Mounjaro Summary of Product Characteristics and Patient Information Leaflet on emc.medicines.org.uk are authoritative. Your UK-registered prescriber decides whether a medicine is appropriate and how it should be used.